Evaluation of doxorubicin-induced early multi-organ toxicity in male CD1 mice by biodistribution of ¹⁸F-FDG and ⁶⁷Ga-citrate. Pilot study

References

• Abdelrahman AM, Al Suleimani YM, Manoj P, Ashique M, Ali BH, Schupp N. 2020. Effect of infliximab, a tumor necrosis factor-alpha inhibitor, on doxorubicin-induced nephrotoxicity in rats. Naunyn Schmiedebergs Arch Pharmacol. 393(1):121–130.
   PubMed Web of Science ®Google Scholar
• Ahn SS, Hwang SH, Jung SM, Lee SW, Park YB, Yun M, Song JJ. 2017. Evaluation of spleen glucose metabolism Using 18F-FDG PET/CT in patients with febrile autoimmune disease. J Nucl Med. 58(3):507–513.
   PubMed Web of Science ®Google Scholar
• Aktaş I, Özmen Ö, Tutun H, Yalçın A, Türk A. 2020. Artemisinin attenuates doxorubicin induced cardiotoxicity and hepatotoxicity in rats. Biotech Histochem. 95(2):121–128.
   PubMed Web of Science ®Google Scholar
• Allam R, Kumar SV, Darisipudi MN, Anders HJ. 2014. Extracellular histones in tissue injury and inflammation. J Mol Med (Berl)). 92(5):465–472.
   PubMed Web of Science ®Google Scholar
• Altınkaynak Y, Kural B, Akcan BA, Bodur A, Özer S, Yuluğ E, Munğan S, Kaya C, Örem A. 2018. Protective effects of L-theanine against doxorubicin-induced nephrotoxicity in rats. Biomed Pharmacother. 108:1524–1534.
   PubMed Web of Science ®Google Scholar
• Ando A, Nitta K, Ando I, Sanada S, Katsuda S, Tonami N, Hiraki T, Hisada K, Ogawa H. 1990. Mechanism of gallium 67 accumulation in inflammatory tissue. Eur J Nucl Med. 17(1-2):21–27.
   PubMedGoogle Scholar
• Araujo FI, Proenca FPP, Ferreira CG, Ventilari SC, Rosado de Castro PH, Moreira RD, Fonseca LMB, Souza SAL, Gutlfilen B. 2015. Use of 99mTc-doxorubicin scintigraphy in females with breast cancer: a pilot study. Br J Radiol. 88(1052):20150268.
   Web of Science ®Google Scholar
• Ayla S, Seckin I, Tanriverdi G, Cengiz M, Eser M, Soner BC, Oktem G. 2011. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol. 2011:390238.
   PubMedGoogle Scholar
• Bartels K, Grenz A, Eltzschig HK. 2013. Hypoxia and inflammation are two sides of the same coin. Proc Natl Acad Sci USA. 110(46):18351–18352.
   PubMed Web of Science ®Google Scholar
• Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. 2009. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 39(2):124–145.
   PubMed Web of Science ®Google Scholar
• Batatinha H, Souza C, Lima E, Alonso-Vale MI, Cruz M, Da Cunha R, Lira F, Rosa J. 2014. Adipose tissue homeostasis is deeply disrupted by doxorubicin treatment. Cancer Metab. 2(S1):P5.
   PubMedGoogle Scholar
• Biondo LA, Lima Junior EA, Souza CO, Cruz MM, Cunha RD, Alonso-Vale MI, Oyama LM, Nascimento CM, Pimentel GD, Dos Santos RV, et al. 2016. Impact of doxorubicin treatment on the physiological functions of white adipose tissue. PLoS One. 11(3):e0151548.
   PubMed Web of Science ®Google Scholar
• Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. 2011. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes. 2011:490650.
   PubMedGoogle Scholar
• Bolotta A, Abruzzo PM, Baldassarro VA, Ghezzo A, Scotlandi K, Marini M, Zucchini C. 2019. New insights into the hepcidin-ferroportin axis and iron homeostasis in iPSC-derived cardiomyocytes from friedreich's ataxia patient. Oxid Med Cell Longev. 2019:7623023.
   PubMed Web of Science ®Google Scholar
• Boukhenouna S, Wilson MA, Bahmed K, Kosmider B. 2018. Reactive oxygen species in chronic obstructive pulmonary disease. Oxid Med Cell Longev. 2018:5730395.
   PubMed Web of Science ®Google Scholar
• Brazzolotto X, Andriollo M, Guiraud P, Favier A, Moulis JM. 2003. Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta. 1593(2-3):209–218.
   PubMed Web of Science ®Google Scholar
• Bulten BF, Sollini M, Boni R, Massri K, de Geus-Oei LF, van Laarhoven HWM, Slart Riemer HJA, Erba PA. 2019. Cardiac molecular pathways influenced by doxorubicin treatment in mice. Sci Rep. 9(1):2514.
   PubMedGoogle Scholar
• Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. 2014. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 34(1):106–135.
   PubMed Web of Science ®Google Scholar
• Chen T, Shen HM, Deng ZY, Yang ZZ, Zhao RL, Wang L, Feng ZP, Liu C, Li WH, Liu ZJ. 2017. A herbal formula, SYKT, reverses doxorubicin‑induced myelosuppression and cardiotoxicity by inhibiting ROS‑mediated apoptosis. Mol Med Rep. 15(4):2057–2066.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang Y, Zhu Z, Liu H, Guo H, Xiong CH, Xie K, Zhang X, Su S. 2016. Protective effect of berberine on doxorubicin‑induced acute hepatorenal toxicity in rats . Mol Med Rep. 13(5):3953–3960.
   PubMed Web of Science ®Google Scholar
• Chitambar CR. 2016. Gallium and its competing roles with iron in biological systems. Biochim Biophys Acta. 1863(8):2044–2053.
   PubMed Web of Science ®Google Scholar
• Chusyd DE, Wang D, Huffman DM, Nagy TR. 2016. Relationships between rodent white adipose white pads and human white adipose fats depots. Front Nutr. 3:10.
   PubMed Web of Science ®Google Scholar
• Cutone A, Luigi R, Ianiro G, Lepant MS, Bonaccorsi di Patti MC, Valenti P, Musci G. 2020. Lactoferrin’s anti-cancer properties: safety selectivity, and wide range of action. Biomolecules. 10(3):456.
   Web of Science ®Google Scholar
• De Angelis A, Cappetta D, Berrino L, Urbanek K. 2018. Doxorubicin cardiotoxicity: multiple targets and translational perspectives. In: Tan W. editor. Cardiotoxicity. London, UK: IntechOpen. Available from: https://www.intechopen.com/books/cardiotoxicity/doxorubicin-cardiotoxicity-multiple-targets-and-translational-perspectives
   Google Scholar
• de Lima Junior EA, Yamashita AS, Pimentel GD, De Sousa LG, Santos RV, Gonçalves CL, Streck EL, de Lira FS, Rosa Neto JC. 2016. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J Cachexia Sarcopenia Muscle. 7(5):615–625.
   PubMed Web of Science ®Google Scholar
• Eirin A, Lerman A, Lerman LO. 2017. The emerging role of mitochondrial targeting in kidney disease. Handb Exp Pharmacol. 240:229–250.
   PubMedGoogle Scholar
• El-Sayed EM, Mansour AM, El-Sawy WS. 2017. Protective effect of proanthocyanidins against doxorubicin-induced nephrotoxicity in rats. J Biochem Mol Toxicol. 31(11):e21965.
   Web of Science ®Google Scholar
• El-Sheikh AA, Morsy MA, Mahmoud MM, Rifaai RA, Abdelrahman AM. 2012. Effect of coenzyme-q10 on Doxorubicin-induced nephrotoxicity in rats. Adv Pharmacol Sci. 2012:981461.
   PubMedGoogle Scholar
• Elsherbiny NM, El-Sherbiny M. 2014. Thymoquinone attenuates Doxorubicin-induced nephrotoxicity in rats: role of Nrf2 and NOX4. Chem Biol Interact. 223:102–108.
   PubMed Web of Science ®Google Scholar
• Engelstad B, Luk SS, Hattner RS. 1982. Altered 67Ga citrate distribution in patients with multiple red blood cell transfusions. AJR Am J Roentgenol. 139(4):755–759.
   PubMed Web of Science ®Google Scholar
• Ertay T, Sencan Eren M, Karaman M, Oktay G, Durak H. 2017. 18F-FDG-PET/CT in initiation and progression of inflammation and infection. Mirt. 26(2):47–52.
   Google Scholar
• Fernández-Real JM, McClain D, Manco M. 2015. Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes. Diabetes Care. 38(11):2169–2176.
   PubMed Web of Science ®Google Scholar
• Gammella E, Maccarinelli F, Buratti P, Recalcati S, Cairo G. 2014. The role of iron in anthracycline cardiotoxicity. Front Pharmacol. 5:25.
   PubMed Web of Science ®Google Scholar
• Ghigo A, Li M, Hirsch E. 2016. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta. 1863(7 Pt B):1916–1925.
   PubMed Web of Science ®Google Scholar
• Ghio AJ, Turi EL, Yang F, Garrick LM, Garrick MD. 2006. Iron homeostasis in the lung. Biol Res. 39(1):67–77.
   PubMed Web of Science ®Google Scholar
• Giraudo C, Evangelista L, Fraia AS, Lupi A, Quaia E, Cecchin D, Casali M. 2020. Molecular imaging of pulmonary inflammation and infection. IJMS. 21(3):894.
   Google Scholar
• Gotama KT, Soetikno V, Louisa M, Arozal W. 2019. Hepatoprotective effects of L-citrulline against doxorubicin-induced liver damage in rats: an analysis of serum biomarkers. Int J App Pharm. 11(1):230–233.
   Google Scholar
• Gül SS, Aygün H. 2019. Cardioprotective effect of vitamin D and melatonin on doxorubicin-induced cardiotoxicity in rat model: an electrocardiographic, scintigraphic and biochemical study. European Res. j. 5(4):649–657.
   Google Scholar
• Guven C, Sevgiler Y, Taskin E. 2018. Mitochondrial Dysfunction Associated with Doxorubicin. In: Taskin E, Guven C, Sevgiler Y. editors Mitochondrial Diseases. London, UK: Intechopen. Available from: https://www.intechopen.com/books/mitochondrial-diseases/mitochondrial-dysfunction-associated-with-doxorubicin
   Google Scholar
• Heart E, Karandrea S, Liang X, Balke ME, Beringer PA, Bobczynski EM, Zayas-Bazán Burgos D, Richardson T, Gray JP. 2016. Mechanisms of doxorubicin toxicity in pancreatic β-cells. Toxicol Sci. 152(2):395–405.
   PubMed Web of Science ®Google Scholar
• Heeba GH, Mahmoud ME. 2016. Dual effects of quercetin in doxorubicin-induced nephrotoxicity in rats and its modulation of the cytotoxic activity of doxorubicin on human carcinoma cells. Environ Toxicol. 31(5):624–636.
   PubMed Web of Science ®Google Scholar
• Hrelia S, Fiorentini D, Maraldi T, Angeloni C, Bordoni A, Biagi PL, Hakim G. 2002. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 1567(1-2):150–156.
   PubMed Web of Science ®Google Scholar
• Jadapalli JK, Wright GW, Kain V, Sherwani MA, Sonkar R, Yusuf N, Halade GV. 2018. Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium . Am J Physiol Heart Circ Physiol. 315(5):H1091–H1100.
   PubMed Web of Science ®Google Scholar
• Kabel AM. 2018. Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: Role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling. Biomed Pharmacother. 97:439–449.
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B. 2020. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol. 29:101394.
   PubMed Web of Science ®Google Scholar
• Keeney JTR, Ren X, Warrier G, Noel T, Powell DK, Brelsfoard JM, Sultana R, Saatman KE, St. Clair DK, Butterfield DA. 2018. Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment (“ ("chemobrain")”). Oncotarget. 9(54):30324–30339.
   PubMedGoogle Scholar
• Khames A, Khalaf MM, Gad AM, Abd El-Raouf OM. 2017. Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats. Eur J Pharmacol. 805:118–124.
   PubMed Web of Science ®Google Scholar
• Kiefmann R, Rifkind JM, Nagababu E, Bhattacharya J. 2008. Red blood cells induce hypoxic lung inflammation. Blood. 111(10):5205–5214.
   PubMed Web of Science ®Google Scholar
• Kim DR, Lee SY, Kim JS, Kim YG, Moon JY, Lee SH, Lee TW, Ihm CG, Jeong KH. 2017. Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy. Biomed Res Int. 2017:7275109.
   PubMed Web of Science ®Google Scholar
• Kim J, Wessling-Resnick M. 2012. The role of iron metabolism in lung inflammation and injury. J Aller Ther. 01(S4):004.
   Google Scholar
• Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. 2002. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 277(19):17179–17187.
   PubMed Web of Science ®Google Scholar
• Kubota K, Tanaka N, Miyata Y, Ohtsu H, Nakahara T, Sakamoto S, Kudo T, Nishiyama Y, Tateishi U, Murakami K, et al. 2021. Comparison of 18F-FDG PET/CT and 67Ga-SPECT for the diagnosis of fever of unknown origin: a multicenter prospective study in Japan. Ann Nucl Med. 35(1):31–46.
   PubMed Web of Science ®Google Scholar
• Kuhn LC. 2015. Iron regulatory proteins and their role in controlling iron metabolism. Metallomics. 7(2):232–243.
   PubMed Web of Science ®Google Scholar
• Lahoti TS, Patel D, Thekkemadom V, Beckett R, Ray SD. 2012. Doxorubicin-induced in vivo nephrotoxicity involves oxidative stress-mediated multiple pro- and anti-apoptotic signaling pathways. Curr Neurovasc Res. 9(4):282–295.
   PubMed Web of Science ®Google Scholar
• Lane DJR, Merlot AM, Huang MLH, Bae DH, Jansson PJ, Sahni S, Kalinowski DS, Richardson DR. 2015. Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease. Biochim Biophys Acta. 1853(5):1130–1144.
   PubMed Web of Science ®Google Scholar
• Martínez-Rodríguez I, Carril JM. 2013. Update on the use of PET radiopharmaceuticals in inflammatory disease. Rev Esp Med Nucl Imagen Mol. 32(6):378–386.
   PubMed Web of Science ®Google Scholar
• Mathis D, Shoelson SE. 2011. Immunometabolism: an emerging frontier. Nat Rev Immunol. 11(2):81–83.
   PubMed Web of Science ®Google Scholar
• Minchin RF, Johnston MR, Schuller HM, Aiken MA, Boyd MR. 1988. Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer. 61(7):1320–1325.
   PubMed Web of Science ®Google Scholar
• Minotti G, Cairo G, Monti E. 1999. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? Faseb J. 13(2):199–212.
   PubMed Web of Science ®Google Scholar
• Mohamed RH, Karam RA, Amer MG. 2011. Epicatechin attenuates doxorubicin-induced brain toxicity: critical role of TNF-α, iNOS and NF-κB. Brain Res Bull. 86(1-2):22–28.
   PubMed Web of Science ®Google Scholar
• Monroy-González AG, Sánchez-Escalona D, Telich-Tarriba JE, Marroquín-Donday L, Juárez-Orozco L, Peñarrieta-Daher E, Valles-Terrazas M, Jiménez M, Alexánderson E. 2012. El uso del PET con 18F-FDG en Cardiología. UPdate. 1(2):33–39.
   Google Scholar
• National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. 2011. Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK54050/ doi:https://doi.org/10.17226/12910
   Google Scholar
• Nebigil CG, Désaubry L. 2018. Updates in anthracycline-mediated cardiotoxicity. Front Pharmacol. 9:1262.
   PubMed Web of Science ®Google Scholar
• Neves J, Haider T, Gassmann M, Muckenthaler MU. 2019. Iron homeostasis in the lungs – a balance between health and Disease. Pharmaceuticals. 12(1):5.
   Web of Science ®Google Scholar
• Nogués IA, Bello AP, Benito IH, Velasco RP, Dólera TM, Navarro AM. 2009. Interstitial nephritis demonstrated by 67Ga-citrate scintigraphy within a diagnosis of fever of unknown origin. Rev Esp Med Nucl. 28(5):242–245.
   PubMed Web of Science ®Google Scholar
• Norma Oficial Mexicana -NOM-062-ZOO-1999. 2002. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio. Gac Méd Méx. 138(3):295–298.
   PubMedGoogle Scholar
• Patil L, Balaraman R. 2009. Effect of melatonin on doxorubicin induced testicular damage in rats. Int J PharmTech Res. 1(3):879–884.
   Google Scholar
• Pereira GC, Silva AM, Diogo CV, Carvalho FS, Monteiro P, Oliveira PJ. 2011. Drug-induced Cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr Pharm Des. 17(20):2113–2129.
   PubMed Web of Science ®Google Scholar
• Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA, Karuppusamy I. 2018. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 200:26–30.
   PubMed Web of Science ®Google Scholar
• Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK, Sultana S. 2013. Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods. 23(5):337–345.
   PubMed Web of Science ®Google Scholar
• Razaq T, Nisar H, Roohi S, Shehzad A, Ahmad I. 2017. Administration of 99mTc-DTPA in combination with doxorubicin alters the radiopharmaceutical biodistribution in rats. Iran J Nucl Med. 25(2):122–128.
   Web of Science ®Google Scholar
• Refaie MM, Amin EF, El-Tahawy NF, Abdelrahman AM. 2016. Possible protective effect of diacerein on doxorubicin-induced nephrotoxicity in rats. J Toxicol. 2016:9507563.
   PubMed Web of Science ®Google Scholar
• Rosen ED, Spiegelman BM. 2014. What we talk about when we talk about fat? Cell. 156 (1-2):20–44.
   PubMed Web of Science ®Google Scholar
• Siques P, Brito J, Pena E. 2018. Reactive oxygen species and pulmonary vasculature during hypobaric hypoxia. Front Physiol. 9:865.
   PubMed Web of Science ®Google Scholar
• Siswanto S, Arozal W, Juniantito V, Grace A, Agustini FD. Nafrialdi 2016. The effect of mangiferin against brain damage caused by oxidative stress and inflammation induced by doxorubicin. HAYATI J Biosci. 23(2):51–55.
   Google Scholar
• Stěrba M, Popelová O, Vávrová A, Jirkovský E, Kovaříková P, Geršl V, Simůnek T. 2013. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal. 18(8):899–929.
   PubMed Web of Science ®Google Scholar
• Su Z, Ye J, Qin Z, Ding X. 2015. Protective effects of madecassoside against Doxorubicin induced nephrotoxicity in vivo and in vitro. Sci Rep. 5:18314.
   PubMed Web of Science ®Google Scholar
• Sultana R, Di Domenico F, Tseng M, Cai J, Noel T, Chelvarajan RL, Pierce WD, Cini C, Bondada S, St Clair DK, et al. 2010. Doxorubicin-induced thymus senescence. J Proteome Res. 9(12):6232–6241.
   PubMed Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR. 2013. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 65(2):157–170.
   PubMed Web of Science ®Google Scholar
• Talbot SR, Biernot S, Bleich A, van Dijk RM, Ernst L, Häger C, Helgers SOA, Koegel B, Koska I, Kuhla A, el al. 2020. Defining body-weight reduction as a humane endpoint: a critical appraisal. Lab Anim. 54(1):99–110.
   PubMedGoogle Scholar
• Tangpong J, Miriyala S, Noel T, Sinthupibulyakit C, Jungsuwadee P, St Clair DK. 2011. Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia mangostana. Neuroscience. 175:292–299.
   PubMed Web of Science ®Google Scholar
• Tangpong J, Sompol P, Vore M, St Clair W, Butterfield DA, St Clair DK. 2008. Tumor necrosis factor alpha-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience. 151(2):622–629.
   PubMed Web of Science ®Google Scholar
• Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. 2006. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 41(3):389–405.
   PubMed Web of Science ®Google Scholar
• Torres VM, Simic VD. 2012. Doxorubicin-induced oxidative injury of cardiomyocytes – do we have right strategies for prevention? In: Fiuza M, editor. Cardiotoxicity of oncologic treatments. London, UK: Intechopen. Available from: https://www.intechopen.com/books/cardiotoxicity-of-oncologic-treatments/doxorubicin-induced-oxidative-injury-of-cardiomyocytes-do-we-have-right-strategies-for-prevention
   Google Scholar
• Tsan MF. 1985. Mechanism of gallium-67 accumulation in inflammatory lesions. J Nucl Med. 26(1):88–92.
   PubMed Web of Science ®Google Scholar
• van Beek L, van Klinken JB, Pronk AC, van Dam AD, Dirven E, Rensen PC, Koning F, Willems van Dijk K, van Harmelen V. 2015. The limited storage capacity of gonadal adipose tissue directs the development of metabolic disorders in male C57Bl/6J mice. Diabetologia. 58(7):1601–1609.
   PubMed Web of Science ®Google Scholar
• Vapa I, Torres VM, Djordjevic A, Vasovic V, Srdjenovic B, Simic VD, Popović JK. 2012. Effect of fullerenol C(60)(OH) (24) on lipid peroxidation of kidneys, testes and lungs in rats treated with ted with doxorubicine. Eur J Drug Metab Pharmacokinet. 37(4):301–307.
   PubMed Web of Science ®Google Scholar
• Walker VJ, Agarwal A. 2016. Targeting iron homeostasis in acute kidney injury. Semin Nephrol. 36(1):62–70.
   PubMed Web of Science ®Google Scholar
• Weiner RE, Spencer RP, Dambro TJ, Klein BE. 1992. Gallium-67 distribution in a man with a decrease in both transferrin and hepatic gallium-67 concentration. J Nucl Med. 33(9):1701–1703.
   PubMed Web of Science ®Google Scholar
• Yurekli Y, Unak P, Ertay T, Biber Z, Medine I, Teksoz S. 2005. Radiopharmaceutical model using 99mTc-MIBI to evaluate amifostine protection against doxorubicin cardiotoxicity in rats. Ann Nucl Med. 19(3):197–200.
   PubMed Web of Science ®Google Scholar
• Zamora E, Valdivia AY, Zalta B, Zuckier LS. 2020. [67Ga] Ga-citrate and COVID-19-associated pneumonia: an unexpected absence of uptake. Eur J Nucl Med Mol Imaging. 47(9):2207–2208.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xu A, Sun X, Yang Y, Zhang L, Bai H, Ben J, Zhu X, Li X, Yang Q, et al. 2020. Self-Maintenance of Cardiac Resident Reparative Macrophages Attenuates Doxorubicin-Induced Cardiomyopathy Through the SR-A1-c-Myc Axis. Circ Res. 127(5):610–627.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang B. 2017. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 7:44735.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang J, Tong N, Chen Y, Luo Y. 2012. Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice. Biol Pharm Bull. 35(5):796–800.
   PubMed Web of Science ®Google Scholar
• Zuckier LS, Valdivia AY, Zamora E. 2020. Does gallium-citrate have yet another story to tell? Lessons relevant to the COVID-19 era. Eur J Nucl Med Mol Imaging. 47(9):2059–2061.
   PubMed Web of Science ®Google Scholar